Ir para o conteúdo principal

Ocular Therapeutix (NASDAQ: OCUL) — Perfil da empresa, notícias e dados financeiros

Logo de Ocular Therapeutix
OCUL Ocular Therapeutix
Ocular Therapeutix primary media
Perfil da empresa

Ocular Therapeutix

Ocular Therapeutix (NASDAQ:OCUL) focuses on the discovery, development, and commercialization of eye care products designed to treat eye disorders with innovative technologies. This healthcare firm leverages its expertise to create products that offer solutions for conditions like glaucoma, eye infections, and inflammatory diseases. Ocular Therapeutix is committed to enhancing the treatment experience for patients through products that aim to improve efficacy, safety, and compliance. Its projects range from preclinical studies to advanced clinical trials, aiming to address unmet medical needs in ophthalmology and bring about a new era of eye care solutions. The objective is to lead through innovation, making significant contributions to eye health and patient care.

Resumo

Public USParticipação acionária
2006Ano de fundação
264Funcionários
Bedford, United StatesSede
Carregando mapa...
Presença global

Operações

Todos os locais
United States

Produtos e/ou serviços de Ocular Therapeutix

  • Dextenza – A corticosteroid intracanalicular insert for postoperative ocular pain and inflammation.
  • OTX-TKI – A bioresorbable hydrogel implant delivering tyrosine kinase inhibitor for wet age-related macular degeneration.
  • OTX-TIC – A sustained-release travoprost implant for reducing intraocular pressure in patients with glaucoma or ocular hypertension.
  • ReSure Sealant – A hydrogel ocular sealant for wound closure following cataract surgery or corneal transplantation.
  • OTX-CSI – A cyclosporine intracanalicular insert for the chronic treatment of dry eye disease.
  • OTX-DED – A development project focused on a hydrogel drug delivery platform for dry eye disease.

equipe executiva do Ocular Therapeutix

  • Pravin U. DugelExecutive Chairman, President & CEO
  • Donald Notman Jr.Chief Operating Officer (Leave of Absence)
  • Steve MeyersChief Commercial Officer
  • Sanjay NayakChief Strategy Officer
  • Nadia K. WaheedChief Medical Officer
  • Jason RobinsCFO & Principal Accounting Officer
  • Peter K. JarrettChief Technical Officer
  • Jeffrey S. HeierChief Scientific Officer
  • William S. Slattery Jr.Vice President of Investor Relations
  • Todd D.C. AndermanChief Legal Officer & Corporate Secretary

Principais indicadores financeiros

Resultados divulgados pela Ocular Therapeutix, em USD.

Cap. de mercado
1,5 bi
Receita (TTM)
52,1 mi
P/L
—
LPA (diluído, TTM)
-1.4
Dividend yield
—
Margem de lucro
0.0%
Receita e lucro anuais da Ocular Therapeutix
Fim do ano fiscalReceitaResultado operacionalLucro líquido
51,8 mi-270 mi-265,9 mi
63,7 mi-171,8 mi-193,5 mi
58,4 mi-82,4 mi-80,7 mi
51,5 mi-78,7 mi-71 mi